Aptevo Therapeutics Stock Analysis

Aptevo Stock Analysis Notes

The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aptevo Therapeutics recorded a loss per share of 87.38. The entity last dividend was issued on the 27th of March 2020. The firm had 1:37 split on the 4th of December 2024. Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Aptevo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people. For more info on Aptevo Therapeutics please contact Marvin White at 206 838 0500 or go to https://aptevotherapeutics.com.

Aptevo Therapeutics Investment Alerts

Aptevo Therapeutics Upcoming and Recent Events

Aptevo Largest EPS Surprises

View All Earnings Estimates

Aptevo Therapeutics Environmental, Social, and Governance (ESG) Scores

Aptevo Stock Institutional Investors

Note, although Aptevo Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aptevo Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.75 M.

Aptevo Profitablity

Management Efficiency

Aptevo Therapeutics has return on total asset (ROA) of (0.7606) % which means that it has lost $0.7606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8428) %, meaning that it created substantial loss on money invested by shareholders. Aptevo Therapeutics' management efficiency ratios could be used to measure how well Aptevo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to grow to -1.47. In addition to that, Return On Capital Employed is likely to drop to -2.75. At this time, Aptevo Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 24th of March 2025, Other Current Assets is likely to grow to about 2.9 M, while Total Assets are likely to drop about 14.8 M.

Technical Drivers

As of the 24th of March, Aptevo Therapeutics shows the Standard Deviation of 5.23, risk adjusted performance of (0.09), and Mean Deviation of 3.94. Aptevo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Aptevo Therapeutics Price Movement Analysis

Aptevo Therapeutics Insider Trading Activities

Aptevo Therapeutics Outstanding Bonds

Aptevo Therapeutics Predictive Daily Indicators

Aptevo Therapeutics Corporate Filings

Aptevo Therapeutics Forecast Models

Aptevo Therapeutics' time-series forecasting models are one of many Aptevo Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aptevo Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aptevo Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aptevo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aptevo Therapeutics. By using and applying Aptevo Stock analysis, traders can create a robust methodology for identifying Aptevo entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aptevo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aptevo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Aptevo Therapeutics stock analysis indicators help investors evaluate how Aptevo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aptevo Therapeutics shares will generate the highest return on investment. By understating and applying Aptevo Therapeutics stock analysis, traders can identify Aptevo Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.